A randomized phase II study of a combination of docetaxel and bevacizumab versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with bevacizumab and platinum-based chemotherapy.
Phase 2
- Conditions
- ung cancer
- Registration Number
- JPRN-UMIN000005214
- Lead Sponsor
- Cancer Institute Ariake Hospital of JFCR
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Not provided
Exclusion Criteria
Subjects with interstitial pneumonia or pulmonary fibrosis. Uncontrolled Active infection. Subjects with brain metastases. Concurrent use of steroid therapy. Uncontrolled pleural. Subjects with previous malignancies. Any other reason that,in the opinion of the investigator precludes the subject from participating in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PFS
- Secondary Outcome Measures
Name Time Method